Glycated Albumin Predicts the Risk of Mortality in Type 2 Diabetic Patients on Hemodialysis: Evaluation of a Target Level for Improving Survival

Therapeutic Apheresis and Dialysis

Volumn 18, Issue 5, 2014, Pages 434-442

  Isshiki, Keiji ^a   Nishio, Toshiki ^e   Isono, Motohide ^b   Makiishi, Tetsuya ^c   Shikano, Tsutomu ^g   Tomita, Koubin ^f   Nishio, Toshiji ^d   Kanasaki, Masami ^a   Maegawa, Hiroshi ^a   Uzu, Takashi ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b Otsu City Hospital   (Japan)

^c OTSU RED CROSS HOSPITAL   (Japan)

^d Seta Clinic   (Japan)

^e Medical Care Center   (Japan)

^f Tomita Dialysis Clinic   (Japan)

^g Second Okamoto Hospital   (Japan)

Author keywords

Diabetic hemodialysis patients; Glycated albumin; HbA1c; Mortality; Random glucose level

Indexed keywords

GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; GLYCOSYLATED SERUM ALBUMIN; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAPAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PREDICTION; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; RISK REDUCTION; SURVIVAL RATE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; KAPLAN MEIER METHOD; METABOLISM; MULTICENTER STUDY; RENAL REPLACEMENT THERAPY;

AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; SERUM ALBUMIN; SURVIVAL RATE;

EID: 84909968716     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12123     Document Type: Article

References (25)

1. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care 1995;18:440-447.
2. Ly J, Marticorena R, Donnelly S. Red blood cell survival in chronic renal failure. Am J Kidney Dis 2004;44:715-719.
3. Peacock TP, Shihabi ZK, Bleyer AJ etal. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 2008;73:1062-1068.
4. Inaba M, Okuno S, Kumeda Y etal. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007;18:896-903.
5. Nakao T, Matsumoto H, Okada T etal. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med 1998;37:826-830.
6. Nagayama H, Inaba M, Okabe R etal. Glycated albumin as an improved indicator of glycemic control in hemodialysis patients with type 2 diabetes based on fasting plasma glucose and oral glucose tolerance test. Biomed Pharmacother 2009;63:236-240.
7. Shima K, Komatsu M, Kawahara K, Minaguchi J, Kawashima S. Stringent glycaemic control prolongs survival in diabetic patients with end-stage renal disease on haemodialysis. Nephrology (Carlton) 2010;15:632-638.
8. Inaba M, Maekawa K, Okuno S etal. Impact of atherosclerosis on the relationship of glycemic control and mortality in diabetic patients on hemodialysis. Clin Nephrol 2012;78:273-280.
9. JH I. Hemoglobin A1c in hemodialysis patients: should one size fit all? Clin J Am Soc Nephrol 2010;5:1539-1541.
10. Kanbay M, Perazella MA, Kasapoglu B, Koroglu M, Covic A. Erythropoiesis stimulatory agent-resistant anemia in dialysis patients: review of causes and management. Blood Purif 2010;29:1-12.
11. Uzu T, Hatta T, Deji N etal. Target for glycemic control in type 2 diabetic patients on hemodialysis: effects of anemia and erythropoietin injection on hemoglobin A(1c). Ther Apher Dial 2009;13:89-94.
12. Okada T, Nakao T, Matsumoto H etal. Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease. Intern Med 2007;46:807-814.
13. Fukuoka K, Nakao K, Morimoto H etal. Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology (Carlton) 2008;13:278-283.
14. Freedman BI, Andries L, Shihabi ZK etal. Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol 2011;6:1635-1643.
15. Kalantar-Zadeh K, Kopple JD, Regidor DL etal. A1C and survival in maintenance hemodialysis patients. Diabetes Care 2007;30:1049-1055.
16. Takahashi S, Uchino H, Shimizu T etal. Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control. Endocr J 2007;54:139-144.
17. Williams ME, Lacson E, Teng M, Ofsthun N, Lazarus JM. Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival. Kidney Int 2006;70:1503-1509.
18. Williams ME, Lacson E, Teng M, Hakim RM, Lazarus JM. Extremes of glycemic control (HbA1c) increase hospitalization risk in diabetic hemodialysis patients in the USA. Am J Nephrol 2009;29:54-61.
19. Ramirez SP, McCullough KP, Thumma JR etal. Hemoglobin A1c levels and mortality in the diabetic hemodialysis population: findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Diabetes Care 2012;35:2527-2532.
20. Ishimura E, Okuno S, Kono K etal. Glycemic control and survival of diabetic hemodialysis patients-importance of lower hemoglobin A1C levels. Diabetes Res Clin Pract 2009;83:320-326.
21. Tsubakihara Y, Nishi S, Akiba T etal. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 2010;14:240-275.
22. Goodkin DA, Bragg-Gresham JL, Koenig KG etal. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003;14:3270-3277.
23. Gerstein HC, Miller ME, Byington RP etal. Effect of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
24. Duckworth W, Abraira C, Moritz T etal. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139.
25. Patel A, MacMahon S, Charlmers J etal. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.